The Tempus AI, Inc. (NASDAQ: TEM) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. Tempus is a healthcare technology company that applies artificial intelligence and multimodal data to precision medicine, and its filings offer insight into how it reports financial performance, manages capital, and documents material corporate events.
Investors can review Form 8-K filings where Tempus discloses items such as preliminary financial results, earnings press releases, credit agreement amendments, securities offerings, and other significant developments. For example, Tempus has used 8-K reports to furnish quarterly financial information, describe an automatic shelf registration statement and related prospectus supplement, and detail the terms of its convertible senior notes due 2030, including conversion features, redemption provisions, and associated capped call transactions.
Over time, this page will also surface Tempus’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically include segment information for its Diagnostics and Data and applications businesses, risk factor discussions, and management’s analysis of operations. In addition, users can expect access to ownership and insider transaction disclosures, such as Form 4 filings, when they are available from EDGAR.
Stock Titan enhances these documents with AI-powered summaries that explain key points from lengthy filings in clear language. Real-time updates from EDGAR help ensure that new TEM filings appear promptly, while AI-generated highlights can draw attention to important terms in credit agreements, securities offerings, or covenant changes. This combination allows readers to navigate Tempus’s regulatory history more efficiently, from capital structure details to ongoing financial reporting.
Frederick Wayne A.I. reported acquisition or exercise transactions in this Form 4 filing.
Tempus AI, Inc. director Frederick Wayne A.I. received an award of 5,913 shares of Class A Common Stock in the form of restricted stock units. These RSUs carry no purchase price and will vest in full on the earlier of the company’s 2027 annual stockholder meeting or May 21, 2027, if he remains in continuous service. Following this equity award, his direct holdings reported in this filing total 30,749 shares of Class A Common Stock.
Epstein David R reported acquisition or exercise transactions in this Form 4 filing.
Tempus AI director David R. Epstein received an award of 5,913 shares of Class A common stock in the form of restricted stock units. The award was granted at no cash cost per share and increased his directly held position to 31,714 shares.
The RSUs will vest in full on the earlier of the company’s 2027 annual stockholder meeting (or immediately before it if his board service ends then) or on May 21, 2027, assuming he continues serving the company through the vesting date.
Doudna Jennifer A reported acquisition or exercise transactions in this Form 4 filing.
Tempus AI, Inc. director Jennifer A. Doudna reported receiving an equity compensation grant in the form of 5,913 shares of Class A common stock as a restricted stock unit (RSU) award. The filing shows she now holds 28,615 shares directly after this grant.
The RSUs will vest in full on the earlier of the company’s 2027 annual stockholder meeting (or immediately before it if her board service ends then) or on May 21, 2027, provided she continues serving as a director through the applicable vesting date. This is a routine, non-cash director compensation award rather than an open-market share purchase or sale.
BARRIS PETER J reported acquisition or exercise transactions in this Form 4 filing.
Tempus AI, Inc. director Peter J. Barris received an equity award equivalent to 5,913 shares of Class A Common Stock in the form of restricted stock units. These RSUs will vest in full on the earlier of the company’s 2027 annual stockholders meeting or May 21, 2027, if he remains in continuous service. Following this grant, he directly holds 121,424 shares.
Tempus AI, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on May 21, 2026. Stockholders, with Class A shares carrying one vote and Class B shares 30 votes per share, elected nine directors to serve until the 2027 annual meeting.
Stockholders also ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 262,396,207 votes for, 90,662 against and 65,045 abstentions. In an advisory vote on how often to hold say-on-pay votes, 191,972,032 votes favored a three-year frequency, compared with 42,744,443 for one year. The board determined future advisory votes on named executive officer compensation will be held every three years.
Tempus AI, Inc. executive Thomas Edward Schoenherr, CEO of Diagnostics, reported a small mandated share sale tied to tax withholding. He sold 1,580 shares of Class A common stock in an open-market transaction at a weighted average price of $44.07 per share. The sale covered statutory tax obligations from vesting restricted stock units under the company’s equity incentive plans and was not a discretionary trade. After this transaction, he directly holds 107,029 shares.
Tempus AI, Inc. Chief Financial Officer James William Rogers reported a mandatory sale of Class A Common Stock tied to equity compensation. He sold 10,853 shares on May 19, 2026 at a weighted average price of $44.07 per share to cover statutory tax withholding on vested restricted stock units. The sale was executed under the company’s “sell to cover” requirement and is described as not a discretionary sale by the executive. After this transaction, he directly holds 126,395 shares of Tempus AI Class A Common Stock.
Tempus AI, Inc. executive Andrew Polovin, EVP and Chief Legal Officer, reported an automatic sale tied to equity compensation. On this Form 4, he sold 8,703 shares of Class A Common Stock at a weighted average price of $44.07 per share to cover statutory tax withholding for vested restricted stock units. The company’s equity plan requires this kind of “sell to cover” transaction, so the sale is not discretionary. After the sale, Polovin directly holds 128,215 shares of Tempus AI Class A Common Stock.
Tempus AI, Inc. CEO and Chairman Eric P. Lefkofsky reported a mandated tax-related share sale. On May 19, entities associated with him reported updated Class A Common Stock holdings, and he sold 22,335 shares at a weighted average of $44.07 per share.
According to the disclosure, this sale was required to cover statutory tax withholding obligations tied to the vesting of restricted stock units under the company’s equity plans and "does not represent a discretionary sale" by Lefkofsky. After the transaction, he directly holds 2,230,721 Class A shares, with additional indirect holdings through entities including Blue Media, LLC, Gray Media, LLC and the Lefkofsky Family 2025 GRAT.
Tempus AI, Inc. executive Fukushima Ryan, who serves as CEO, Data, reported an open-market sale of 13,550 shares of Class A Common Stock at a weighted average price of $44.07 per share. According to the footnotes, this transaction was a mandated “sell to cover” to satisfy statutory tax withholding obligations arising from the vesting of restricted stock units, and is not a discretionary sale. Following the transaction, he holds 603,558 shares directly and an additional 211,047 shares indirectly through his spouse.